Tarceva erlotinib: Phase III started

The National Clinical Trials Network (NCTN) launched the ALCHEMIST protocol to identify early stage NSCLC patients with tumors that harbor genetic mutations to understand how early intervention can improve survival outcomes for patients who have undergone complete

Read the full 376 word article

User Sign In